Is the era of Monsanto tyranny finally coming to an end? These numbers seem to affirm the biotech giant is failing
NaturalNews.com
Tuesday, August 23, 2016
Share prices — plummeting. Royalties — cut. Consumer opinion — in the toilet. Governments — fed up. Monsanto’s earnings represent the writing on the wall, but the company’s glory days are nearing an end[1] for many reasons ranging from farmer and consumer resistance to government crackdowns on GMO products and even Monsanto’s best-selling chemical product, glyphosate. Monsanto’s days are about as numbered as a fruit fly’s.
(Article by Christina Sarich, republished from http://undergroundreporter.org)
If we were to ascertain Monsanto’s financial health by their stock price alone, you could safely say that they are suffering. The company recently slashed its 2016 earnings forecast from the $5.10-$5.60 per share it had forecast in December, to $4.40-$5.10, claiming that the reduction was due to a lagging strength in the U.S. dollar — but there’s much more to the picture.
The Rest…HERE
